Researcher Profile

Researcher Profile

Salah Almokadem, MD

Salah Almokadem, MD

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Head and Neck Cancer
Thoracic Cancer
sma11@psu.edu

Research Interests

  • Therapeutics
  • Neoplasms
  • volociximab
  • Non-Small Cell Lung Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Pharmacokinetics
  • Integrins
  • Safety
  • Clinical Trials
  • Survival
  • Squamous Cell Carcinoma
  • Docetaxel

Clinical Trials

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)(KEYNOTE-867) MK 3475-867
NRG-HN005 - A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer
Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Recent Publications

2019

KEYNOTE-040 investigators 2019, 'Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study', The Lancet, vol. 393, no. 10167, pp. 156-167. https://doi.org/10.1016/S0140-6736(18)31999-8

2017

Liu, J, Goldenberg, D, Almokadem, S, Crist, H & Mackley, HB 2017, 'Long-term recurrence-free survival after an unplanned reduction in radiotherapy for HPV-positive oropharyngeal SCC: Two cases and a review of the literature', Ear, Nose and Throat Journal, vol. 96, no. 7, E23. https://doi.org/10.1177/014556131709600705
Stoller, R, Schmitz, JC, Ding, F, Puhalla, S, Belani, CP, Appleman, L, Lin, Y, Jiang, Y, Almokadem, S, Petro, D, Holleran, J, Kiesel, BF, Ken Czambel, R, Carneiro, BA, Kontopodis, E, Hershberger, PA, Rachid, M, Chen, A, Chu, E & Beumer, JH 2017, 'Phase I study of veliparib in combination with gemcitabine', Cancer Chemotherapy and Pharmacology, vol. 80, no. 3, pp. 631-643. https://doi.org/10.1007/s00280-017-3409-3

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)